Cencora Splits Into Two Reportable Segments, And Its Specialty Arm Posts A 3.73% Margin

Cencora recast fiscal 2026 and 2025 results under the structure it will use from fiscal 2027, with total revenue of $337.4 billion.

Share
Cencora Splits Into Two Reportable Segments, And Its Specialty Arm Posts A 3.73% Margin

Cencora, which distributes pharmaceuticals and healthcare products, said in an 8-K filed Wednesday that it will report under two segments plus an "Other" group starting in the first quarter of fiscal 2027, and it recast two years of results to show the effect. On the new basis, fiscal 2026 revenue was $337,397,299 thousand.

Specialty margin widens

Total segment operating income for fiscal 2026 reached $4,813,047 thousand on the revised basis, up from $4,222,973 thousand in fiscal 2025. Revenue for fiscal 2025 was $321,332,819 thousand. The figures are unaudited, and the company furnished them voluntarily to help investors follow the change.

Specialty Pharmaceutical and Provider Services earned an operating margin of 3.73% of revenue in fiscal 2026, against 3.22% a year earlier. Its revenue was $45,390,532 thousand, and operating income was $1,693,022 thousand.

Pharmaceutical Distribution and Services, the far larger segment, brought in $284,484,156 thousand of revenue at a 0.96% margin, up from 0.92%. Other added $8,739,921 thousand of revenue and a 4.50% margin. Intersegment eliminations took $1,217,310 thousand off fiscal 2026 revenue, versus $1,258,352 thousand in fiscal 2025.

Who lands in which bucket

Cencora said it recently completed a restructuring of its operating model, meant to strengthen execution and improve visibility. The change reorganizes every business that sat in the U.S. Healthcare Solutions and International Healthcare Solutions segments.

Pharmaceutical Distribution and Services will cover U.S. and international wholesale distribution and related services for health systems, retail pharmacies and alternate sites of care. Specialty Pharmaceutical and Provider Services will hold specialty distribution to physician practices, management services organizations, World Courier, third-party logistics, Innomar and strategic components of PharmaLex.

Other is not a reportable segment. It groups MWI Animal Health, Profarma and the remaining PharmaLex businesses, which Cencora said it is exploring strategic alternatives for.

The business behind the numbers

Cencora's customers include pharmacies, hospitals and specialty physician practices, including oncology and retina specialists. It has recently invested in or bought practice management and physician specialty network organizations, the kind of business the specialty segment now gathers. As of September 30, 2025, Walgreens and Boots together accounted for about 38% of its net accounts receivable.

The first quarter of fiscal 2027 will be the first period Cencora reports under the new structure.

Sources

More on Cencora

All Cencora (COR) coverage →